Innovation Is a Team Effort: Turning Diagnostic “Sparks” Into Clinical Impact
June 10, 2026 - Lenexa, KS, USA
Innovation in diagnostics rarely happens in isolation. It is sparked by clinical need, informed by science, and realized through collaboration. At Eurofins Viracor, innovation is not confined to a single team or discipline, it’s a shared responsibility that drives our mission to provide clear, actionable insights for patient care.
From first-in-class assays to advanced molecular testing that supports emerging therapies, our approach to innovation is grounded in a simple principle: when diagnostic testing evolves in step with medicine, patient care advances faster.
Innovation Driven by Clinical Need
Healthcare providers face increasingly complex decisions, especially in areas such as transplantation, infectious disease, and advanced cancer therapies. The role of diagnostic testing is no longer limited to confirmation of disease; it now plays a critical role in therapy selection, treatment monitoring, and outcome prediction.
In early 2026, Eurofins Viracor expanded its test menu with two notable launches:
- A comprehensive 32-serotype pneumococcal antibody panel, providing enhanced insight into immune response following vaccination
- ExPeCT obe-cel, a qPCR assay designed to measure levels of a newly approved CAR T-cell therapy
Both assays were developed and launched in close alignment with new FDA approvals, ensuring clinicians had timely access to tools that support real-world clinical decision making.
Where New Test Ideas Begin: Listening for “Sparks”
The most impactful innovations often begin as early, unpolished ideas…what we call “sparks.” These sparks emerge through conversations with healthcare providers and clinical thought leaders, close review of scientific literature, monitoring unmet diagnostic needs, and insight gained through conferences and professional collaboration.
Transforming a spark into a clinically validated assay takes insight, persistence, and teamwork. Through regular evaluation and cross-functional planning, ideas are refined into tests that address real clinical gaps.
From Local Innovation to Global Impact
Eurofins Viracor’s collaborative approach to innovation reflects a broader Eurofins philosophy. In the recently released Eurofins Innovation Booklet, teams from across the organization are highlighted for translating ideas into meaningful advances in patient care. Eurofins Viracor is proud to be featured for its contributions to diagnostic innovation in oncology.
Our section, “Providing Insights Into Cancer Treatment Success”, showcases how specialized testing supports clinical decision making in advanced cancer therapies and demonstrates how locally sparked innovations can scale globally.
Supporting Advanced Cancer Therapies Through Diagnostics
Modern oncology increasingly relies on diagnostics to evaluate treatment response and guide therapy decisions. As cancer treatments grow more individualized, clinicians depend on companion diagnostics that deliver reliable, actionable insights. Eurofins Viracor’s work in this space reflects a commitment to supporting advanced therapies with precise diagnostic solutions.
Embracing Bold Ideas
Not every spark becomes a successful assay. Innovation requires a willingness to explore new ideas, embrace calculated risk, and remain focused on improving patient outcomes. The opportunities for diagnostic advancement have never been greater, and progress depends on curiosity, collaboration, and courage.
Advancing Care, Together
By listening closely to clinical needs, investing in innovation, and collaborating across teams and geographies, Eurofins Viracor continues to turn diagnostic sparks into meaningful impact for patients worldwide.
Leading Edge Monitoring of CAR T-cell Therapy
